Navigation Links
Weikang Bio-Technology to Present at Rodman & Renshaw Annual China Investment Conference
Date:3/4/2011

HARBIN, China, March 4, 2011 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that the Company will be presenting at the Rodman & Renshaw Annual China Investment Conference.

The event will be held March 6-8, 2011, at Le Royal Meridien Shanghai in Shanghai, China. Weikang is scheduled to make its presentation on March 8, 2011 at 2:25 PM local time in Parlour V. Investors interested in additional information about Weikang Bio-Technology or arranging a one-on-one meeting with company executives at this conference should contact Jon Cunningham at 407-644-4256, Ext. 107, or email info@redchip.com.

About Weikang Bio-Technology Group Co., Inc.Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang Pharmaceutical Co., Ltd.  For more information, please visit http://www.weikangbio.com.

Safe Harbor StatementCertain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.Investor Relations Contact:Paul Kuntz, Senior SpecialistRedChip Companies, Inc.Tel: +1-800-733-2447, Ext. 0Email: info@redchip.comJing Zhang, Chief RepresentativeRedChip Companies Beijing OfficeTel: +86 10-8591-0635Web: http://www.RedChip.com
'/>"/>

SOURCE Weikang Bio-Technology Group Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List
2. Weikang Bio-Technology Expects to Report Fiscal 2010 Revenue of $77.8 Million and Net Income of $31.2 Million or $1.04 Earnings per Share
3. Weikang Bio-Technology Plans to Launch New Therapeutics in First Quarter 2011
4. Weikang Bio-Technology to Present at Global Hunter 2010 China Conference on July 13, 2010
5. Weikang Bio-Technology Announces Filing for NASDAQ Listing
6. Weikang Bio-Technology Reports First Quarter 2010 Financial Results
7. Neuro Kinetics Presenting New Balance & Dizziness Research at American Balance Society Conference
8. Thoratec Announces Presentations at Upcoming Investor Conferences
9. Masimo to Present at the Roth Growth Stock Conference
10. DK Sinopharma, Inc. is to Present at the Rodman & Renshaw Annual China Investment Conference to be Held March 6--8
11. Awarepoint Invited to Present at Cowen & Company 31st Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  Visage Imaging Inc. ... Ltd. (ASX: PME), has announced that the American College ... (UF) have selected the Visage 7 Enterprise Imaging ... the Emergent/Critical Care Imaging SIMulation (SIM). SIM is ... Imaging Program (WIDI), a multi-faceted and fully-integrated online ...
(Date:2/10/2016)... DIEGO , Feb. 10, 2016 ... company developing novel, clinical-stage therapies for sickle cell disease ... underwritten public offering of 29,090,910 units at a price ... consists of one share of the Company,s common stock ... Company,s common stock at an exercise price of $0.42 ...
(Date:2/10/2016)... Antibacterial Drugs Market - Global Industry ... ", reveals that the global antibacterial drugs market is forecast ... owing to patent expiries of blockbuster drugs. Even though the ... forecast period, the value is anticipated to decline from US$43.9 ... Antibacterial Drugs Market - Global Industry Analysis, Size, Share, ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix ... of Emergency Medicine , an emergency medicine professional association, to support the organization's ... , The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency ...
(Date:2/10/2016)... SAN FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... category: Best Water Brand. There were three leading bottled water brand owners that topped ... edge services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 Executive Forum, ... 200 of the country’s top healthcare executives to share insights on transformational strategies ... the Forum is the provider-centric perspective, experience, expertise and strategy shared by the ...
(Date:2/10/2016)... ... 2016 , ... Armune BioScience signed a definitive agreement with ... centers across the country. Launched in April of 2015, Apifiny is the only cancer ... Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... it will attend the Ohio Safety Congress and Expo event March 9-11, 2016. ... the Greater Columbus Convention Center. , As the longest running and largest ...
Breaking Medicine News(10 mins):